The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program

Neuroimaging with MRI has been a frequent component of studies of individuals at clinical high risk (CHR) for developing psychosis, with goals of understanding potential brain regions and systems impacted in the CHR state and identifying prognostic or predictive biomarkers that can enhance our ability to forecast clinical outcomes. To date, most studies involving MRI in CHR are likely not sufficiently powered to generate robust and generalizable neuroimaging results. Here, we describe the prospective, advanced, and modern neuroimaging protocol that was implemented in a complex multi-site, multi-vendor environment, as part of the large-scale Accelerating Medicines Partnership® Schizophrenia Program (AMP® SCZ), including the rationale for various choices. This protocol includes T1- and T2-weighted structural scans, resting-state fMRI, and diffusion-weighted imaging collected at two time points, approximately 2 months apart. We also present preliminary variance component analyses of several measures, such as signal- and contrast-to-noise ratio (SNR/CNR) and spatial smoothness, to provide quantitative data on the relative percentages of participant, site, and platform (i.e., scanner model) variance. Site-related variance is generally small (typically <10%). For the SNR/CNR measures from the structural and fMRI scans, participant variance is the largest component (as desired; 40-76%). However, for SNR/CNR in the diffusion scans, there is substantial platform-related variance (>55%) due to differences in the diffusion imaging hardware capabilities of the different scanners. Also, spatial smoothness generally has a large platform-related variance due to inherent, difficult to control, differences between vendors in their acquisitions and reconstructions. These results illustrate some of the factors that will need to be considered in analyses of the AMP SCZ neuroimaging data, which will be the largest CHR cohort to date.Watch Dr. Harms discuss this article at https://vimeo.com/1059777228?share=copy#t=0 .

Authors

Institutions

Publication Details

Journal
Schizophrenia
Published
2025-04-02
DOI
https://doi.org/10.1038/s41537-025-00581-6
Citations
7
Primary Topic
Functional Brain Connectivity Studies
Type
article
Field-Weighted Citation Impact
10.02

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program

Sylvain Bouix, Celso Arango, Barbara A. Cornblatt, Alan Anticevic et al.
7 citations
Schizophrenia
Functional Brain Connectivity Studies
10.02
article

The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program

Sylvain Bouix, Celso Arango, Barbara A. Cornblatt, Alan Anticevic, Joshua Kuperman, John M. Kane, Lipeng Ning, Diana O. Perkins, Christopher J. Markiewicz, Jai L. Shah, Albert R. Powers, Godfrey D. Pearlson, Carrie E. Bearden, Fred W. Sabb, Kerstin Langbein, Nicholas J. K. Breitborde, Jason Eric Schiffman, Gregory P. Strauss, Jijun Wang, Philippe Conus, Daniel H. Mathalon, Luis Alameda, Walid Yassin, Ulrich Lindberg, Anastasia Haidar, Swapna Verma, Lana Kambeitz‐Ilankovic, Jun Soo Kwon, Stephen James Wood, René S. Kahn, Matthew R. Broome, Juan Helen Zhou, Michael P. Harms, Covadonga M. Díaz‐Caneja, Merete Nordentoft, Yogesh Rathi, Steven M. Silverstein, Jack Rogers, Carla Gerber, Mathias Goncalves, Kristen Laulette, Russell A. Poldrack, Christy Lai Ming Hui, Barnaby Nelson, Pablo A. Gaspar, Judy L. Thompson, Nicholas Kim, Jean Addington, Cheryl M. Corcoran, Jesús Pérez, Rachel Upthegrove, William S. Stone, Patrick D. McGorry, Paolo Fusar‐Poli, Marek Kubicki, Guillermo Cecchi, Nicolas R. Bolo, Paul Romo, Zailyn Tamayo, Monica E. Calkins, Scott W. Woods, Stefan Smesny, Kristin S. Cadenhead, Omar John, Martha E. Shenton, Cassandra M. J. Wannan, Daniel H. Wolf, Igor Izyurov, Joseph Kambeitz, Vijay Anand Mittal, Tyrone D. Cannon, Leslie E. Horton, Nikolaos Koutsouleris, Tina Kapur, Elana Kotler, Kang Ik K. Cho, Sung‐Wan Kim, Eric Yu Hai Chen, Jimmy Choi, Louise Birkedal Glenthøj, Alana Wickham, Matcheri S. Keshavan, Lauren M. Ellman, David R. Campbell, Dylan Hughes
article en
7 citations

Abstract

Neuroimaging with MRI has been a frequent component of studies of individuals at clinical high risk (CHR) for developing psychosis, with goals of understanding potential brain regions and systems impacted in the CHR state and identifying prognostic or predictive biomarkers that can enhance our ability to forecast clinical outcomes. To date, most studies involving MRI in CHR are likely not sufficiently powered to generate robust and generalizable neuroimaging results. Here, we describe the prospective, advanced, and modern neuroimaging protocol that was implemented in a complex multi-site, multi-vendor environment, as part of the large-scale Accelerating Medicines Partnership® Schizophrenia Program (AMP® SCZ), including the rationale for various choices. This protocol includes T1- and T2-weighted structural scans, resting-state fMRI, and diffusion-weighted imaging collected at two time points, approximately 2 months apart. We also present preliminary variance component analyses of several measures, such as signal- and contrast-to-noise ratio (SNR/CNR) and spatial smoothness, to provide quantitative data on the relative percentages of participant, site, and platform (i.e., scanner model) variance. Site-related variance is generally small (typically <10%). For the SNR/CNR measures from the structural and fMRI scans, participant variance is the largest component (as desired; 40-76%). However, for SNR/CNR in the diffusion scans, there is substantial platform-related variance (>55%) due to differences in the diffusion imaging hardware capabilities of the different scanners. Also, spatial smoothness generally has a large platform-related variance due to inherent, difficult to control, differences between vendors in their acquisitions and reconstructions. These results illustrate some of the factors that will need to be considered in analyses of the AMP SCZ neuroimaging data, which will be the largest CHR cohort to date.Watch Dr. Harms discuss this article at https://vimeo.com/1059777228?share=copy#t=0 .

SchizophreniaVol. 11(1)
Chonnam National University (KR), Northwestern University (US), University of North Carolina at Chapel Hill (US), University of Copenhagen (DK), Brigham and Women's Hospital (US), Beth Israel Deaconess Medical Center (US), Oregon Research Institute (US), Feinstein Institute for Medical Research (US), IBM (United States) (US), Harvard University (US), Seoul National University (KR), University of California, Los Angeles (US), University of Georgia (US), The University of Melbourne (AU), National University of Singapore (SG), University of Calgary (CA), University of Pittsburgh (US), Chinese University of Hong Kong (HK), University of California, San Francisco (US), University of Cologne (DE), University of Oregon (US), King's College London (GB), Universidad de Salamanca (ES), University of California, Irvine (US), Washington University in St. Louis (US), University of Pavia (IT), Glostrup Hospital (DK), Copenhagen University Hospital (DK), Shanghai Mental Health Center (CN), The Ohio State University Wexner Medical Center (US), University of Rochester Medical Center (US), Hospital General Universitario Gregorio Marañón (ES), Yale University (US), University of California San Diego (US), Massachusetts General Hospital (US), Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US), Orygen (AU), IBM Research - Thomas J. Watson Research Center (US), Jena University Hospital (DE), Behavioral Health Network (US), Institute of Mental Health (SG), San Francisco VA Health Care System (US), Cambridgeshire and Peterborough NHS Foundation Trust (GB), University Hospital Cologne (DE), Birmingham Women’s and Children’s NHS Foundation Trust (GB), Connecticut Mental Health Center (US), Hotchkiss Brain Institute (CA), McGill University (CA), The Ohio State University (US), University of Chile (CL), University of Pennsylvania (US), University of Birmingham (GB), Ludwig-Maximilians-Universität München (DE), Temple University (US), University of Hong Kong (HK), Stanford University (US), École de Technologie Supérieure (CA), University of Lausanne (CH), Icahn School of Medicine at Mount Sinai (US)
Bristol-Myers Squibb, Pfizer, Wellcome, Biogen, Teva Pharmaceutical Industries, Sunovion, Indivior, Gedeon Richter, Servier, H. Lundbeck A/S, HLS Therapeutics, National Institutes of Health, Allergan, National Institute of Mental Health, Cilag
Partnerships for the goals
Openalex Percentile: Top 2%
Functional Brain Connectivity Studies
10.02
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.